Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2408 in healthy subjects
NCT02125435Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2011
- Primary completion
- May 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) and transplant rejection comparing ASP2408 Arm with Placebo Arm (2 arms). Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration at 90 days, Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity at 90 days and 2 more. Started Jan 2011; status: completed.
02
Drugs
ASP2408
03
Conditions
rheumatoid arthritis (RA)transplant rejection
Beyond the preview
Go deeper on NCT02125435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125435.